Get started
Author

Anshul Gupta

ORCID: 0000-0001-9128-3840
Observed ORCID: 0000-0001-9128-3840
OpenAlex ID: A5048500025
Neoadjuvant chemotherapy with or without anthracyclines in combination with single HER2-targeted therapy in HER2-positive breast cancer
2023 · Anshul Gupta, Ajay Gogia, et al. · Cancer Treatment and Research Communications · 2
Safety, efficacy and survival outcome of Ado-trastuzumab emtansine (T-DM1) in patients with metastatic HER2-positive breast cancer: An Indian experience.
2022 · Ajay Gogia, Anshul Gupta, et al. · Journal of Clinical Oncology · 2
Lenvatinib plus pembrolizumab for advanced endometrial cancer
2022 · Anshul Gupta, Ajay Gogia · Cancer Research Statistics and Treatment · 2
Outcome with pertuzumab, docetaxel, and trastuzumab (PTH) regimen in patients with HER2 positive metastatic breast cancer: Real-world data from a single center in India.
2024 · Ajay Gogia, Anshul Gupta, et al. · Journal of Clinical Oncology · 1
Neoadjuvant pertuzumab, docetaxel, carboplatin, and trastuzumab (PTCH) regimen in patients with HER2 positive early, locally advanced, and oligometastatic breast cancer: Real-world Indian experience.
2024 · Ajay Gogia, Anshul Gupta, et al. · Journal of Clinical Oncology
Outcomes of neoadjuvant combination chemotherapy with and without targeted therapy in HER2-positive breast cancer: A real-world experience from tertiary care center in North India.
2022 · Anshul Gupta, Ajay Gogia, et al. · Journal of Clinical Oncology
A real-world experience of TCH (docetaxel/carboplatin/trastuzumab) regimen in early, locally advanced and oligometastatic HER2 positive breast cancer from tertiary care center in North India.
2022 · Anshul Gupta, Ajay Gogia, et al. · Journal of Clinical Oncology
Ribociclib-induced flagellate rash
2022 · Anshul Gupta, Ajay Gogia · Cancer Research Statistics and Treatment
Works count: 8
Citation count: 7
H-index: 2
I10-index:
Year
Topic
Type